Non-Hodgkin Lymphoma (NHL) Market Growth Analysis

Market Insights

The Non-Hodgkin Lymphoma (NHL) Market is projected to grow from USD 8.1 Billion in 2020 to USD 12.4 Billion by 2026 at a CAGR of around 7.4% during the forecast period.

Wish to get a free sample? Register Here

What is non-hodgkin lymphoma?

Non-Hodgkin lymphoma also referred to as non-Hodgkin's lymphoma, NHL, or lymphoma is a type of cancer that starts in white blood cells called lymphocytes, a part of the body’s immune system. The various types of drugs used to treat Non-Hodgkin lymphoma include monoclonal antibodies, antibody-drug conjugates, btk/bcl-2 kinase inhibitors, pi3 kinase inhibitors, protease inhibitors, and others.

Key Players

Key players operating in the Non-Hodgkin Lymphoma (NHL) market are-

• F. Hoffmann-La Roche AG (Switzerland)
• Johnson & Johnson (US)
• The Merck Group (Germany)
• Bristol Myers Squibb (US)
• Celgene Corporation (US)
• Eli Lilly and Company (US)
• GlaxoSmithKline plc (UK)
• Bayer AG (Germany)
• AstraZeneca plc (UK)
• The Takeda Pharmaceutical Company Limited (Japan).

Market Dynamics

The growth of the non-Hodgkin lymphoma (NHL) market is primarily driven by increasing incidences of lymphoma cancer disease across geographies. Changing lifestyles and unhealthy diets are some of the factors resulting in cancer disease, which is likely to drive the market growth at a significant rate during the review period. In addition to this, surging demand for new cancer treatment drugs is likely to create lucrative opportunities for the players operating in the global market in the coming years.

COVID-19 Impact

The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the number of visits to the hospital for cancer treatment due to the high focus on treating covid-19 patients and the fear of infection.

To get the full scope of the report, Register Here

Segment Analysis

Application Trends

The non-Hodgkin lymphoma (NHL) market has been bifurcated into hospitals and clinics. Under these, the hospital segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment growth can be attributed to the presence of established infrastructure and skilled healthcare staff.

Regional Analysis

The market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The segment growth is primarily attributed to the rising number of people suffering from lymphoma cancer coupled with the presence of key market players such as Bristol Myers Squibb (US) and Celgene Corporation (US). The market growth in the Asia-Pacific region is expected to be driven by the increasing prevalence of cancer disease.

To get the full scope of the report, Register Here

Target Audience

Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-

• Distributors
• Suppliers
• Manufacturers
• Logistics organizations
• Government bodies

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What deliverables will you get in this report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.